Schall, Brown & Schwartz LLP filed a class action lawsuit against Beta Bionics for allegedly making false statements about the safety and regulatory status of its iLet Bionic Pancreas insulin pump. The complaint claims Beta Bionics misled investors by downplaying FDA concerns about the device's quality management and unreported serious injuries. As these issues came to light, Beta Bionics' stock price dropped, causing losses to shareholders who bought shares between July 30, 2025, and February 24, 2026. Investors have until November 3, 2026, to join the lawsuit or seek lead plaintiff status.
The Alternative for Germany (AfD) won nearly 44% of the vote in Saxony-Anhalt, securing 39 of 83 state parliament seats, strengthening its stance against removing Germany's one-year tax exemption on Bitcoin and other cryptocurrencies. This election r...
Zcash's price surged to around $1,130 after a 2,300% gain over the past year, entering the crypto top ten. F2Pool co-founder Chun Wang publicly criticized Zcash's funding structure, governance disputes, and optional privacy model, highlighting concer...
Cronos blockchain suffered a $120.4 million exploit when an attacker manipulated the price of TONIC token to borrow funds from Tectonic lending markets. Validators halted the network and rolled back nearly two hours of transactions, restoring $111.2 ...
Pump.fun, a Solana-based memecoin launchpad, has reclaimed the top spot in 24-hour protocol revenue with about $1.23 million in fees, overtaking Pons, a newer competitor that had briefly led earlier in 2026. Pons gained rapid traction by leveraging R...
Boyaa Interactive purchased about 205 Bitcoin for $14.3 million between June and September 2026, increasing its total Bitcoin holdings to approximately 4,316 BTC at an average cost of $68,280 per Bitcoin. The company funded these purchases with cash ...
